Kissei Pharmaceutical Co., Ltd. (KSPHF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kissei Pharmaceutical Co., Ltd. (KSPHF) with AI Score 50/100 (Hold). Kissei Pharmaceutical Co. , Ltd. is a Japanese pharmaceutical company focused on researching, developing, manufacturing, and selling specialized drugs. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Kissei Pharmaceutical Co., Ltd. (KSPHF) Healthcare & Pipeline Overview
Kissei Pharmaceutical Co., Ltd., based in Japan, develops and markets specialty pharmaceutical products, focusing on therapeutic areas like dysuria, diabetes, and renal anemia. With a strong presence in the domestic market, Kissei leverages its research and development pipeline to address unmet medical needs and maintain a competitive edge in the generic drug sector.
Investment Thesis
Kissei Pharmaceutical Co., Ltd. presents a compelling investment case based on its established presence in the Japanese pharmaceutical market and a diversified pipeline of drugs targeting various therapeutic areas. With a P/E ratio of 13.18 and a profit margin of 14.8%, the company demonstrates financial stability. Key growth catalysts include the potential approval and commercialization of drugs in Phase III clinical trials, such as KPS-0373 for spinocerebellar ataxia and AJM300 for ulcerative colitis. The company's dividend yield of 2.34% offers an additional incentive for investors. However, potential risks include regulatory hurdles, competition from generic drug manufacturers, and the inherent uncertainty associated with pharmaceutical research and development.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $1.07 billion, reflecting a substantial valuation in the specialty pharmaceutical sector.
- P/E ratio of 13.18, indicating a potentially undervalued stock compared to industry peers.
- Profit margin of 14.8%, demonstrating efficient operations and profitability.
- Gross margin of 48.2%, showcasing strong pricing power and cost management.
- Dividend yield of 2.34%, providing a steady income stream for investors.
Competitors & Peers
Strengths
- Strong presence in the Japanese pharmaceutical market.
- Diversified product portfolio targeting various therapeutic areas.
- Robust pipeline of drugs in Phase III clinical trials.
- Established relationships with healthcare providers and distributors.
Weaknesses
- Limited geographic diversification, primarily focused on Japan.
- Dependence on regulatory approvals for new drug launches.
- Exposure to pricing pressures from generic drug manufacturers.
- Potential for clinical trial failures and delays.
Catalysts
- Upcoming: Potential regulatory approval and commercialization of KPS-0373 for spinocerebellar ataxia.
- Upcoming: Potential regulatory approval and commercialization of AJM300 for ulcerative colitis.
- Ongoing: Progress in clinical trials for other drugs in the pipeline, including treatments for microscopic polyangiitis and uremic pruritus.
- Ongoing: Strategic alliances and partnerships with other pharmaceutical companies.
- Ongoing: Expansion into new therapeutic areas and markets.
Risks
- Potential: Failure or delays in clinical trials for drugs in the pipeline.
- Potential: Regulatory hurdles and delays in obtaining drug approvals.
- Ongoing: Competition from generic drug manufacturers and pricing pressures.
- Ongoing: Dependence on the Japanese pharmaceutical market.
- Potential: Changes in government healthcare policies and reimbursement rates.
Growth Opportunities
- Expansion of Product Portfolio: Kissei has several products in Phase III clinical trials, including KPS-0373 for spinocerebellar ataxia and AJM300 for ulcerative colitis. Successful completion of these trials and subsequent regulatory approvals could significantly expand Kissei's product portfolio and revenue streams. The market for spinocerebellar ataxia treatments is estimated to grow, driven by increasing awareness and diagnosis rates. Timeline: 2027-2028.
- Geographic Expansion: While Kissei primarily operates in Japan, there is potential for geographic expansion into other Asian markets or through partnerships with international pharmaceutical companies. Expanding into new markets could diversify Kissei's revenue base and reduce its reliance on the Japanese market. The Asian pharmaceutical market is experiencing rapid growth, driven by increasing healthcare expenditure and access to medicines. Timeline: 2028-2030.
- Strategic Alliances and Partnerships: Kissei can pursue strategic alliances and partnerships with other pharmaceutical companies to co-develop and co-market drugs. This could accelerate the development and commercialization of new products and expand Kissei's market reach. Collaborations can also provide access to new technologies and expertise. Timeline: Ongoing.
- Focus on Specialty Drugs: Kissei's focus on specialty drugs, particularly in areas like dysuria, diabetes, and renal anemia, positions it well to capitalize on the growing demand for targeted therapies. Specialty drugs often command higher prices and offer greater profit margins compared to generic drugs. The global market for specialty drugs is projected to grow, driven by advances in biotechnology and personalized medicine. Timeline: Ongoing.
- Investment in Research and Development: Kissei's commitment to research and development is crucial for maintaining a competitive edge in the pharmaceutical industry. Continued investment in R&D can lead to the discovery and development of innovative new drugs and therapies. A strong R&D pipeline is essential for long-term growth and value creation. Timeline: Ongoing.
Opportunities
- Expansion into new therapeutic areas and markets.
- Strategic alliances and partnerships with other pharmaceutical companies.
- Increased demand for specialty drugs and targeted therapies.
- Growing aging population in Japan and increasing healthcare expenditure.
Threats
- Competition from domestic and international pharmaceutical companies.
- Changes in government healthcare policies and reimbursement rates.
- Patent expirations and generic drug entry.
- Economic downturns and fluctuations in currency exchange rates.
Competitive Advantages
- Patent protection for innovative drugs, providing exclusivity and pricing power.
- Established brand reputation and relationships with healthcare providers in Japan.
- Specialized knowledge and expertise in specific therapeutic areas.
- Strong research and development capabilities, enabling the development of new drugs and therapies.
About KSPHF
Kissei Pharmaceutical Co., Ltd., established in 1946 and headquartered in Matsumoto, Japan, has evolved into a research-driven pharmaceutical company. Originally named Kissei Yakuhin Kogyo Co., Ltd., the company adopted its current name in 1964. Kissei focuses on the development, manufacture, and sale of pharmaceutical products, primarily within Japan. Its product portfolio includes Urief and Urief OD tablets for dysuria, Glufast, Glubes, and Marizev tablets for type 2 diabetes, Darbepoetin Alfa BS and Epoetin Alfa BS injections for renal anemia, Beova tablets for overactive bladder, P-TOL chewable tablets for hyperphosphatemia, and Minirin Melt OD tablets for nocturia. The company's pipeline features several drugs in Phase III clinical trials, targeting conditions such as spinocerebellar ataxia, microscopic polyangiitis, ulcerative colitis, chronic idiopathic thrombocytopenic purpura, and uremic pruritus. Additionally, Kissei is developing treatments for endometriosis, uterine fibroids, Parkinson's disease, and asthma. Beyond pharmaceuticals, Kissei also produces and sells protein-controlled and energy-supply foods, along with related materials. The company provides system development, information processing, construction contracting, equipment and facility management, and information gathering and development support services.
What They Do
- Researches and develops pharmaceutical products.
- Manufactures pharmaceutical products.
- Sells pharmaceutical products, primarily in Japan.
- Offers Urief and Urief OD tablets for the treatment of dysuria.
- Provides Glufast, Glubes, and Marizev tablets for type 2 diabetes.
- Offers Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia.
- Develops and sells protein controlled and energy supply foods.
- Offers system development and information processing services.
Business Model
- Develops and patents pharmaceutical products.
- Manufactures drugs for specific therapeutic areas.
- Markets and sells drugs through established distribution channels in Japan.
- Generates revenue through sales of prescription drugs and related healthcare products.
Industry Context
Kissei Pharmaceutical Co., Ltd. operates in the competitive Japanese pharmaceutical market, characterized by a growing aging population and increasing demand for specialized treatments. The industry is driven by innovation, regulatory approvals, and pricing pressures. Kissei competes with both domestic and international pharmaceutical companies, including BIOGY, CHIZF, CMOPF, EVOTF, and LJUIF, focusing on niche therapeutic areas and generic drugs. The market is also influenced by government healthcare policies and reimbursement rates, which impact the profitability of pharmaceutical companies.
Key Customers
- Patients with conditions such as dysuria, type 2 diabetes, and renal anemia.
- Hospitals and clinics that prescribe and administer Kissei's drugs.
- Pharmacies that dispense Kissei's drugs to patients.
- Healthcare providers who recommend Kissei's products.
Financials
Chart & Info
Kissei Pharmaceutical Co., Ltd. (KSPHF) stock price: Price data unavailable
Latest News
No recent news available for KSPHF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KSPHF.
Price Targets
Wall Street price target analysis for KSPHF.
MoonshotScore
What does this score mean?
The MoonshotScore rates KSPHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Mutsuo Kanzawa
Unknown
Information on Mutsuo Kanzawa's background is not available in the provided context. Details regarding his career history, education, and previous roles are unknown. Further research would be required to provide a comprehensive profile of his professional experience.
Track Record: Information on Mutsuo Kanzawa's track record and key achievements as CEO is not available in the provided context. Specific milestones and strategic decisions made under his leadership are unknown. Additional research would be needed to assess his performance and contributions to Kissei Pharmaceutical Co., Ltd.
KSPHF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Kissei Pharmaceutical Co., Ltd. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and disclosure requirements.
- Potential for low trading volume and illiquidity.
- Increased risk of fraud or manipulation.
- Greater price volatility compared to stocks listed on major exchanges.
- Limited availability of company information and financial data.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Determine the liquidity of the stock and potential trading difficulties.
- Consult with a financial advisor before investing.
- Check for any news or reports about potential red flags.
- Established history of operations since 1946.
- Focus on research and development of pharmaceutical products.
- Presence in the Japanese pharmaceutical market.
- Pipeline of drugs in Phase III clinical trials.
- Dividend yield of 2.34%.
Common Questions About KSPHF
What does Kissei Pharmaceutical Co., Ltd. do?
Kissei Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company that researches, develops, manufactures, and sells pharmaceutical products, primarily in Japan. The company focuses on specialty drugs for therapeutic areas such as dysuria, type 2 diabetes, renal anemia, and overactive bladder. Kissei's business model involves developing and patenting innovative drugs, manufacturing them, and marketing them through established distribution channels. The company also generates revenue through the sale of protein-controlled and energy-supply foods and related services.
What do analysts say about KSPHF stock?
AI analysis is pending for Kissei Pharmaceutical Co., Ltd. (KSPHF). Therefore, a summary of analyst consensus, key valuation metrics, and growth considerations is currently unavailable. Investors should consult with a financial advisor and conduct their own due diligence before making any investment decisions. Further information will be provided once the AI analysis is complete.
What are the main risks for KSPHF?
Kissei Pharmaceutical Co., Ltd. faces several risks, including the potential for clinical trial failures or delays, regulatory hurdles in obtaining drug approvals, and competition from generic drug manufacturers. The company's dependence on the Japanese pharmaceutical market also poses a risk, as changes in government healthcare policies and reimbursement rates could impact its profitability. Additionally, economic downturns and fluctuations in currency exchange rates could affect Kissei's financial performance.
What are the key factors to evaluate for KSPHF?
Kissei Pharmaceutical Co., Ltd. (KSPHF) currently holds an AI score of 50/100, indicating moderate score. Key strength: Strong presence in the Japanese pharmaceutical market.. Primary risk to monitor: Potential: Failure or delays in clinical trials for drugs in the pipeline.. This is not financial advice.
How frequently does KSPHF data refresh on this page?
KSPHF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven KSPHF's recent stock price performance?
Recent price movement in Kissei Pharmaceutical Co., Ltd. (KSPHF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong presence in the Japanese pharmaceutical market.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider KSPHF overvalued or undervalued right now?
Determining whether Kissei Pharmaceutical Co., Ltd. (KSPHF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying KSPHF?
Before investing in Kissei Pharmaceutical Co., Ltd. (KSPHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than data from major exchanges.
- AI analysis is pending and may provide additional insights.